Saturday, December 20, 2025

Latest

Starbucks: Analysts Expect Q4 Earnings of $0.99 Per Share

Starbucks (NASDAQ: SBUX) will be reporting its fourth quarter financial results today after the markets close. Analysts have a consensus $129.25 12-month price target on the company, via a total of 37 analysts, with 12 analysts having strong buy ratings. 10 analysts meanwhile have buy ratings, 14 analysts have a hold rating and a single analyst has a sell rating on the company. The street high comes from Kalinowski Equity Research with a $148 price target, and the lowest target sits at $95.

26 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 26 analysts is $8.21 billion; this number has been revised upwards from $8.07 billion at the start of April. The highest revenue estimate is $8.45 billion, while the lowest is $7.92 billion.

Onto EBITDA estimates, there are currently 18 analysts who have fourth-quarter EBITDA estimates. The mean is currently $1.93 billion, with this number having been revised upwards from $1.9 billion at the start of April. The street high estimate currently sits at $2.05 billion in EBITDA and the lowest is $1.85 billion.

Analysts estimate that quarterly earnings per share will come in at $0.99, with this number being revised upwards from $0.96 at the start of April. Street high is $1.05 and the lowest estimate is $10.93 per share for the quarter.


Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Soma Gold: Q3 Earnings Impacted By Labour Strike

Thesis Gold: The Multi-Billion Dollar Lawyers-Ranch PFS

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Recommended

Northern Superior Shareholders Set To Receive Shares Of ONGold Resources Friday

Goliath Resources Sees Rob McEwen Increase Ownership Interest

Related News

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Trulieve: Canaccord Raises Price Target From $45 To $51

Last week, Trulieve Cannabis (CSE: TRUL) announced that they are acquiring two Pennsylvania companies, PurePen...

Tuesday, September 22, 2020, 02:45:00 PM

Canaccord Downgrades Alimentation Couche-Tard Ahead Of Q4 Results

Ahead of Alimentation Couche-Tard’s (TSX: ATD.B) fiscal fourth-quarter results, Canaccord Genuity has downgraded the company...

Tuesday, June 22, 2021, 11:36:00 AM

Paypal: Analysts Forecast Q2 Revenues Of $6.26 Billion

Paypal (NASDAQ: PYPL) will be reporting its second quarter financial results today after market close....

Wednesday, July 28, 2021, 03:03:00 PM

BMO Upgrades Nuvei To Outperform After Short Seller Report

This past week, Spruce Point Capital Management released a report on Nuvei Corporation (TSX: NVEI),...

Sunday, December 12, 2021, 01:05:00 PM